Signaling proteins as innovative targets for antineoplastic therapy: our experience with the signaling protein c-myc

Tumori. 2001 Nov-Dec;87(6):S20-3.

Authors

G Cimoli¹, L Bagnasco, M P Pescarolo, C Avignolo, A Melchiori, S Pasa, B Biasotti, M Taningher, S Parodi

Affiliation

¹ Department of Oncology Biology and Genetics, University of Genoa, Italy.

PMID: 11989613

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / pharmacology*
Benzamides
ErbB Receptors / antagonists & inhibitors
Humans
Imatinib Mesylate
Phospholipases A
Piperazines / pharmacology
Protein Prenylation / drug effects
Proteins / drug effects*
Proteins / metabolism
Proto-Oncogene Proteins / drug effects
Proto-Oncogene Proteins c-myc / drug effects
Proto-Oncogene Proteins p21(ras)
Pyrimidines / pharmacology
Receptors, Retinoic Acid / drug effects
Retinoic Acid Receptor alpha
Signal Transduction / drug effects*
Trastuzumab
ras Proteins

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Benzamides
KRAS protein, human
Piperazines
Proteins
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-myc
Pyrimidines
RARA protein, human
Receptors, Retinoic Acid
Retinoic Acid Receptor alpha
Imatinib Mesylate
ErbB Receptors
PLAAT1 protein, human
Phospholipases A
Proto-Oncogene Proteins p21(ras)
ras Proteins
Trastuzumab